Cue Biopharma Inc.

3.20-0.1400-4.19%Vol 101.93K1Y Perf -67.13%
Aug 16th, 2022 16:00 DELAYED
BID3.15 ASK3.24
Open3.33 Previous Close3.34
Pre-Market- After-Market3.20
 - -  - -%
Target Price
23.00 
Analyst Rating
Strong Buy 1.00
Potential %
618.75 
Finscreener Ranking
★★★★★     59.97
Insiders Trans % 3/6/12 mo.
100/100/-9 
Value Ranking
★★+     48.86
Insiders Value % 3/6/12 mo.
100/100/59 
Growth Ranking
★★★★+     60.44
Insiders Shares Cnt. % 3/6/12 mo.
100/100/87 
Income Ranking
 —    -
Price Range Ratio 52W %
5.23 
Earnings Rating
Strong Buy
Market Cap113.22M 
Earnings Date
8th Aug 2022
Alpha-0.03 Standard Deviation0.21
Beta1.74 

Today's Price Range

3.160.00

52W Range

2.3618.42

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Buy
Performance
1 Week
-0.93%
1 Month
21.67%
3 Months
-14.67%
6 Months
-50.69%
1 Year
-67.13%
3 Years
-59.95%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
CUE3.20-0.1400-4.19
AAPL173.03-0.1600-0.09
GOOG122.51-0.3700-0.30
MSFT292.71-0.7600-0.26
XOM91.46-0.8600-0.93
WFC46.060.31000.68
JNJ167.571.48000.89
FB196.640.99000.51
GE81.071.26001.58
JPM123.631.17000.96
 
ProfitabilityValueIndustryS&P 500US Markets
-
-412.50
-412.50
-
-
RevenueValueIndustryS&P 500US Markets
11.68M
0.33
96.04
-
Earnings HistoryEstimateReportedSurprise %
Q02 2022-0.42-0.3711.90
Q01 2022-0.43-0.44-2.33
Q03 2021-0.39-0.41-5.13
Q02 2021-0.42-0.3321.43
Q01 2021-0.37-0.41-10.81
Q04 2020-0.33-0.37-12.12
Q03 2020-0.37-0.348.11
Q02 2020-0.41-0.387.32
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.424.55Positive
9/2022 QR-0.440.00-
12/2022 FY-1.560.64Positive
12/2023 FY-1.693.43Positive
Next Report Date-
Estimated EPS Next Report-0.42
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume101.93K
Shares Outstanding35.38K
Shares Float33.49M
Trades Count1.44K
Dollar Volume327.98K
Avg. Volume259.11K
Avg. Weekly Volume241.68K
Avg. Monthly Volume183.55K
Avg. Quarterly Volume352.11K

Cue Biopharma Inc. (NASDAQ: CUE) stock closed at 3.2 per share at the end of the most recent trading day (a -4.19% change compared to the prior day closing price) with a volume of 101.93K shares and market capitalization of 113.22M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 47 people. Cue Biopharma Inc. CEO is Daniel R. Passeri.

The one-year performance of Cue Biopharma Inc. stock is -67.13%, while year-to-date (YTD) performance is -71.71%. CUE stock has a five-year performance of %. Its 52-week range is between 2.3601 and 18.42, which gives CUE stock a 52-week price range ratio of 5.23%

Cue Biopharma Inc. currently has a PE ratio of -2.30, a price-to-book (PB) ratio of 2.00, a price-to-sale (PS) ratio of 10.12, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -56.00%, a ROC of -62.19% and a ROE of -73.63%. The company’s profit margin is -%, its EBITDA margin is -412.50%, and its revenue ttm is $11.68 Million , which makes it $0.33 revenue per share.

Of the last four earnings reports from Cue Biopharma Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.42 for the next earnings report. Cue Biopharma Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Cue Biopharma Inc. is Strong Buy (1), with a target price of $23, which is +618.75% compared to the current price. The earnings rating for Cue Biopharma Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Cue Biopharma Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Cue Biopharma Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 15.32, ATR14 : 0.22, CCI20 : 133.31, Chaikin Money Flow : 0.14, MACD : 0.11, Money Flow Index : 79.12, ROC : 27.48, RSI : 55.96, STOCH (14,3) : 90.20, STOCH RSI : 0.94, UO : 57.24, Williams %R : -9.80), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Cue Biopharma Inc. in the last 12-months were: Aaron G.L. Fletcher (Buy at a value of $4 210 300), Anish Suri (Option Excercise at a value of $322 880), Anish Suri (Sold 48 000 shares of value $750 400 ), Cameron Gray (Option Excercise at a value of $165 000), Daniel R. Passeri (Buy at a value of $50 051), Daniel R. Passeri (Option Excercise at a value of $0), Frank Morich (Buy at a value of $105 000), Kerri-Ann Millar (Option Excercise at a value of $9 383), Kerri-Ann Millar (Sold 1 251 shares of value $17 783 ), Peter A. Kiener (Option Excercise at a value of $57 703), Peter A. Kiener (Sold 20 176 shares of value $361 690 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
2 (100.00 %)
2 (100.00 %)
2 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Cue Biopharma Inc.

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologic drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its lead drug candidate comprises CUE-101, a variant form of the cytokine Interleukin-2 and a T cell antigen to target and activate T cells specific to HPV-related cancers.

CEO: Daniel R. Passeri

Telephone: +1 617 949-2680

Address: 21 Erie Street, Cambridge 02139, MA, US

Number of employees: 47

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

56%44%

Bearish Bullish

68%32%

Bearish Bullish

56%44%

TipRanks News for CUE


News

Stocktwits